Jim Cramer explains why Johnson & Johnson rallied after 'surprise' earnings results
-
最新报道：Johnson & Johnson shares surged 5% following strong Q2 earnings, with CEO Joaquin Duato highlighting a 12% revenue jump in pharmaceutical sales driven by blockbuster drugs like Stelara and Darzalex. CNBC's Jim Cramer noted the rally reflects investor confidence in J&J's diversified healthcare portfolio, despite ongoing talc litigation risks. The company raised full-year profit guidance to $10.75-$10.95 per share, beating analyst estimates, while medical device sales grew 8% with recovery in elective procedures. Cramer suggested the stock's underperformance earlier this year created buying opportunities, as J&J demonstrates resilience across all three business segments.
下一篇
Cramer's Lightning Round: Cameco is 'a winner'
- Cameco, a leading uranium producer, is positioned as a strong investment according to Jim ...
24小时热点
热点专题
413635